Shockwave Reducer Demonstrates Consistent, Positive Results in 'Real-World' Study

Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory AnginaSANTA CLARA, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced that investigators presented six-month data from the full population of the REDUCER-I study, alongside interim long-term follow-up results

Related Keywords

United Kingdom ,Brompton ,Medway ,Harefield ,Hillingdon ,Belgium ,Canada ,United States ,Utrecht ,Netherlands ,De Hoef ,Noord Holland ,London ,City Of ,Canadian ,Stefan Verheye ,Scott Shadiow ,Michael Foley ,Debbie Kaster ,Rasha Al Lamee ,European Union ,Nasdaq ,Lung Institute ,Imperial College ,National Heart ,Shockwave Medical Inc ,Canadian Cardiovascular Society ,University Medical Center Utrecht ,Exchange Commission ,Six Month Results ,Trial Add ,Positive Evidence ,Coronary Sinus Reducer ,Treat Refractory ,Shockwave Reducer ,Annual Scientific Sessions ,American College ,Ranil De Silva ,Royal Brompton ,Harefield Hospitals ,New England Journal ,Principal Investigator ,Shockwave Coronary Sinus ,Shockwave Medical ,Intravascular Lithotripsy ,Breakthrough Device ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Refractory Angina ,Ymptoms Of Angina ,Observational Study ,Cardiovascular Disease ,Reducer ,Treatment Options ,